Andra AP fonden Increases Stake in Alnylam Pharmaceuticals, Inc. $ALNY

Andra AP fonden raised its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 200.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 20,700 shares of the biopharmaceutical company’s stock after purchasing an additional 13,800 shares during the period. Andra AP fonden’s holdings in Alnylam Pharmaceuticals were worth $9,439,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth $27,000. Atlantic Union Bankshares Corp bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $30,000. ORG Partners LLC raised its position in shares of Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 33 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $37,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.5%

Shares of NASDAQ:ALNY opened at $332.92 on Friday. The business’s 50-day moving average is $360.54 and its 200 day moving average is $418.95. The firm has a market capitalization of $44.15 billion, a P/E ratio of 194.69 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the previous year, the business earned ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 9,577 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the sale, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This trade represents a 10.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tolga Tanguler sold 1,959 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at $9,850,931.52. This trade represents a 5.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 36,578 shares of company stock worth $12,416,105 in the last three months. 1.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on ALNY. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 20th. Truist Financial dropped their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Stifel Nicolaus increased their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Wells Fargo & Company cut their target price on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.